INKT
MiNK Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+22/100
Last price
11.70
▼ 0.50 (4.10%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
12.20
Prev close
12.20
Day high
12.20
Day low
11.63
Volume
32.72K
Market cap
$59.71M
P/E (TTM)
—
52W range
8.48 – 16.93
Day trading desk
Gap from prior close
+0.00%
Prior close 12.20
VWAP
11.95
-2.11% from price
Relative volume
2.36×
Unusually busy
Session range
4.90%
11.63 – 12.20
Position in range
12%
Near session low
ATR (14D)
0.69
5.86% of price
Prior day high
12.84
PDH
Prior day low
12.10
PDL
Bid / ask spread
—
Quote not published
Session volume
32.72K
Avg 13.88K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.57%
-6.5%
1M
+0.52%
-0.6%
3M
+10.90%
+6.4%
6M
+0.86%
-17.3%
YTD
+4.93%
-9.3%
1Y
-22.08%
-38.5%
3Y
+6.36%
-75.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on INKT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+19.45K
Net buying
Buy transactions
10
20.95K shares
Sell transactions
1
1.50K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
3.03M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | BEHNER PETER Director |
STOCK | 1.49K | $16.26K | Direct |
| Sep 1, 26 | HOLCOMB JOHN BRADLEY M.D. Director |
STOCK | 1.23K | $13.50K | Direct |
| Sep 1, 26 | WIINBERG ULF Director |
STOCK | 1.28K | $14.01K | Direct |
| Sep 1, 26 | CORVESE BRIAN J Director |
STOCK | 1.63K | $17.88K | Direct |
| Sep 1, 26 | RYAN BARBARA Director |
STOCK | 1.62K | $17.76K | Direct |
| Jun 4, 26 | RYAN BARBARA Director |
SELL | 1.50K | $19.14K | Direct |
| Jun 1, 26 | BEHNER PETER Director |
STOCK | 2.80K | $32.51K | Direct |
| Jun 1, 26 | HOLCOMB JOHN BRADLEY M.D. Director |
STOCK | 2.33K | $27.01K | Direct |
| Jun 1, 26 | WIINBERG ULF Director |
STOCK | 2.42K | $28.01K | Direct |
| Jun 1, 26 | CORVESE BRIAN J Director |
STOCK | 3.08K | $35.75K | Direct |
| Jun 1, 26 | RYAN BARBARA Director |
STOCK | 3.06K | $35.51K | Direct |
| Mar 10, 26 | RYAN BARBARA Director |
SELL | 1.50K | $22.05K | Direct |
| Mar 2, 26 | RYAN BARBARA Director |
SELL | 500 | $5.43K | Direct |
| Jan 2, 26 | BUELL JENNIFER Chief Executive Officer |
STOCK | 31.47K | $349.99K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEHNER PETER |
Director | 24.40K | Stock Award(Grant) |
BUELL JENNIFER |
Chief Executive Officer | 67.97K | Stock Award(Grant) |
CORVESE BRIAN J |
Director | 54.77K | Stock Award(Grant) |
HOLCOMB JOHN BRADLEY M.D. |
Director | 4.69K | Stock Award(Grant) |
KADLEC ROBERT PETER |
Director | 19.13K | Stock Award(Grant) |
RYAN BARBARA |
Director | 23.59K | Stock Award(Grant) |
WIINBERG ULF |
Director | 51.76K | Stock Award(Grant) |
Fundamentals
Market cap$59.71M
Enterprise value$50.90M
Revenue (TTM)—
Gross profit—
EBITDA$-11.83M
Net income$-11.36M
EPS (TTM)$-2.29
Free cash flow$-5.35M
Total cash$8.81M
Total debt$0
Book value / share$-2.75
Shares outstanding5.10M
Float2.08M
Short % of float2.24%
Dividend yield0.00%
Beta (5Y)0.47
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.42
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-4.30
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-123.84%
Debt / equity—
Current ratio1.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $5.76M | $6.34M | $15.49M | $23.12M | -9.1% |
| Selling, general & admin | $6.73M | $4.31M | $7.43M | $7.83M | +56.0% |
| Total operating expense | $12.49M | $10.65M | $22.92M | $30.95M | +17.2% |
| Operating income | -$12.49M | -$10.65M | -$22.92M | -$30.95M | -17.2% |
| Net interest income | $180.25K | $172.57K | $463.26K | $253.32K | +4.4% |
| Pre-tax income | -$12.49M | -$10.78M | -$22.46M | -$27.99M | -15.9% |
| Net income | -$12.49M | -$10.78M | -$22.46M | -$27.99M | -15.9% |
| Net income to common | -$12.49M | -$10.78M | -$22.46M | -$27.99M | -15.9% |
| Basic EPS | -2.93 | -2.86 | -6.54 | -8.30 | -2.4% |
| Diluted EPS | -2.93 | -2.86 | -6.54 | -8.30 | -2.4% |
| EBIT | -$12.49M | -$10.65M | -$22.92M | -$30.95M | -17.2% |
| EBITDA | -$12.31M | -$10.43M | -$22.72M | -$30.83M | -17.9% |
| Basic shares | 4.27M | 3.77M | 3.44M | 3.37M | +13.2% |
| Diluted shares | 4.27M | 3.77M | 3.44M | 3.37M | +13.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $13.36M | $4.58M | $3.37M | $19.64M | +191.9% |
| Cash & short-term investments | $13.36M | $4.58M | $3.37M | $19.64M | +191.9% |
| Total current assets | $13.85M | $4.99M | $3.60M | $20.40M | +177.6% |
| Property, plant & equipment | $390.87K | $732.93K | $953.98K | $1.07M | -46.7% |
| Total assets | $14.24M | $5.72M | $4.55M | $21.47M | +148.9% |
| Total current liabilities | $13.03M | $6.96M | $11.40M | $12.68M | +87.2% |
| Current debt | $5.18M | — | — | — | — |
| Long-term debt | — | $4.92M | — | — | — |
| Total debt | $5.18M | $4.92M | — | — | +5.2% |
| Total liabilities | $28.47M | $25.31M | $22.61M | $21.87M | +12.5% |
| Retained earnings | -$156.68M | -$144.18M | -$133.40M | -$110.94M | -8.7% |
| Shareholder equity | -$14.23M | -$19.59M | -$18.06M | -$401.30K | +27.4% |
| Working capital | $816.52K | -$1.97M | -$7.80M | $7.72M | +141.4% |
| Net tangible assets | -$14.23M | -$19.59M | -$18.06M | -$401.30K | +27.4% |
| Shares issued | 4.71M | 3.96M | 3.46M | 3.39M | +18.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$12.49M | -$10.78M | -$22.46M | -$27.99M | — | -15.9% |
| Depreciation & amortisation | $181.75K | $215.44K | $204.62K | $121.75K | — | -15.6% |
| Stock-based compensation | $2.67M | $1.81M | $3.86M | $3.03M | — | +47.7% |
| Change in working capital | $3.29M | $459.73K | $2.90M | $8.77M | — | +615.4% |
| Operating cash flow | -$5.93M | -$9.56M | -$15.76M | -$18.87M | — | +38.0% |
| Capital expenditure | — | — | -$73.56K | -$250.05K | -$248.98K | — |
| Investing cash flow | — | $0 | -$73.56K | -$250.05K | -$248.98K | — |
| Share buybacks | — | $0 | -$477.64K | -$157.19K | $0 | — |
| Financing cash flow | $14.72M | $10.82M | -$407.17K | -$155.60K | — | +36.1% |
| Free cash flow | -$5.93M | -$9.56M | -$15.84M | -$19.12M | — | +38.0% |
| End cash position | $13.36M | $4.58M | $3.37M | $19.64M | — | +191.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $1.89M | $1.20M | $1.51M | $1.14M | $1.84M | — | +56.7% |
| Selling, general & admin | $1.33M | $1.68M | $1.76M | $1.85M | $1.85M | — | -20.7% |
| Total operating expense | $3.22M | $2.88M | $3.28M | $2.99M | $3.69M | — | +11.6% |
| Operating income | -$3.22M | -$2.88M | -$3.28M | -$2.99M | -$3.69M | — | -11.6% |
| Net interest income | $72.88K | $80.83K | $111.23K | $55.15K | $348 | — | -9.8% |
| Pre-tax income | -$3.13M | -$2.74M | -$2.60M | -$2.89M | -$4.24M | — | -14.1% |
| Net income | -$3.13M | -$2.74M | -$2.60M | -$2.89M | -$4.24M | — | -14.1% |
| Net income to common | -$3.13M | -$2.74M | -$2.60M | -$2.89M | -$4.24M | — | -14.1% |
| Basic EPS | -0.62 | -0.57 | — | -0.65 | -1.06 | -0.70 | -8.8% |
| Diluted EPS | -0.62 | -0.57 | — | -0.65 | -1.06 | -0.70 | -8.8% |
| EBIT | -$3.22M | -$2.88M | -$3.28M | -$2.99M | -$3.69M | — | -11.6% |
| EBITDA | -$3.18M | -$2.85M | -$3.24M | -$2.95M | -$3.64M | — | -11.8% |
| Basic shares | 5.02M | 4.80M | — | 4.44M | 3.98M | 3.96M | +4.7% |
| Diluted shares | 5.02M | 4.80M | — | 4.44M | 3.98M | 3.96M | +4.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.81M | $9.53M | $13.36M | $14.28M | $1.68M | — | -7.5% |
| Cash & short-term investments | $8.81M | $9.53M | $13.36M | $14.28M | $1.68M | — | -7.5% |
| Total current assets | $9.30M | $10.02M | $13.85M | $14.53M | $2.01M | — | -7.2% |
| Property, plant & equipment | $318.47K | $354.52K | $390.87K | $429.34K | $473.21K | — | -10.2% |
| Total assets | $9.62M | $10.38M | $14.24M | $14.96M | $2.48M | — | -7.3% |
| Total current liabilities | $7.57M | $7.29M | $13.03M | $13.43M | $13.16M | — | +3.9% |
| Current debt | — | — | $5.18M | $5.73M | $5.51M | $5.12M | — |
| Total debt | — | — | $5.18M | $5.73M | $5.51M | $5.12M | — |
| Total liabilities | $23.64M | $23.06M | $28.47M | $28.48M | $27.67M | — | +2.5% |
| Retained earnings | -$162.55M | -$159.42M | -$156.68M | -$154.07M | -$151.19M | — | -2.0% |
| Shareholder equity | -$14.03M | -$12.69M | -$14.23M | -$13.51M | -$25.19M | — | -10.6% |
| Working capital | $1.73M | $2.74M | $816.52K | $1.10M | -$11.15M | — | -36.8% |
| Net tangible assets | -$14.03M | -$12.69M | -$14.23M | -$13.51M | -$25.19M | — | -10.6% |
| Shares issued | 5.10M | 4.97M | 4.71M | 4.60M | 3.99M | — | +2.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.13M | -$2.74M | -$2.60M | -$2.89M | -$4.24M | -14.1% |
| Depreciation & amortisation | $36.06K | $36.07K | $38.56K | $43.65K | $48.76K | -0.0% |
| Stock-based compensation | $422.20K | $630.39K | $565.77K | $620.59K | $896.55K | -33.0% |
| Change in working capital | $587.12K | $343.32K | $469.36K | $1.06M | $1.17M | +71.0% |
| Operating cash flow | -$2.08M | -$1.73M | -$2.07M | -$941.35K | -$1.57M | -20.2% |
| Financing cash flow | $1.37M | -$2.10M | $1.18M | $13.55M | $540 | +165.0% |
| Free cash flow | -$2.08M | -$1.73M | -$2.07M | -$941.35K | -$1.57M | -20.2% |
| End cash position | $8.81M | $9.53M | $13.36M | $14.28M | $1.68M | -7.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.60 | -0.62 | -3.3% |
| Mar 2026 | -0.77 | -0.57 | +26.0% |
| Dec 2025 | -0.68 | -0.56 | +17.7% |
| Sep 2025 | -0.86 | -0.65 | +24.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 1 | $1.60M | 0.0% |
| Next quarter | -0.39 | 1 | $1.80M | 0.0% |
| Current year | -1.93 | 1 | $3.40M | 0.0% |
| Next year | -1.97 | 1 | $4.00M | +17.7% |
Analyst targets & ownership
Mean target$39.00
High target$43.00
Low target$35.00
Implied upside233.33%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders59.37%
Held by institutions4.01%
Institutions holding30
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.28
-4.74% from price
SMA 20
12.10
-3.28% from price
SMA 50
11.58
+1.01% from price
SMA 100
11.49
+1.81% from price
SMA 200
11.42
+2.45% from price
EMA 12
12.17
-3.84% from price
EMA 26
11.98
-2.36% from price
EMA 50
11.76
-0.52% from price
RSI (14)
45.9
Neutral
MACD (12,26,9)
0.18
Hist -0.04
ATR (14)
0.69
5.86% of price
Realised vol 30D
37.8%
Annualised
Bollinger upper
12.73
20, 2σ
Bollinger lower
11.46
20, 2σ
50 / 200 cross
Golden
11.58 vs 11.42
Trend bias
Above 200
+2.45%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.69
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
37.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-43.6%
Peak to trough
Max drawdown 5Y
-97.7%
Peak to trough
ATR 14
0.69
5.86% of price
Beta (reported)
0.47
5Y monthly, from filing
Short interest
Shares short
57.14K
Prior 78.32K
Change vs prior
-27.0%
Shorts covering
% of float
2.24%
Normal
% of shares out
1.12%
Against total outstanding
Days to cover
4.1
Liquid
Float
2.08M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 25 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Jul 15, 25 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jul 14, 25 | William Blair | DOWNGRADE | Outperform | Market Perform |
| Mar 18, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 15, 24 | Baird | MAINTAINED | Outperform | Outperform |
| Nov 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 9, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 13, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJan 28, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-05-15
Corporate Changes & Voting Matters
8-K · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-03-27
Corporate Changes & Voting Matters
8-K · 2026-03-19
Corporate Changes & Voting Matters
8-K · 2026-01-02
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2025-12-10
Headlines
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
GlobeNewswire · 5d ago
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
GlobeNewswire · 7d ago
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 54d ago
MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...
GuruFocus.com · 54d ago
MiNK Therapeutics Q2 Earnings Call Highlights
MarketBeat · 55d ago
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
GlobeNewswire · 55d ago
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
GlobeNewswire · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.